BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 33225985)

  • 1. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
    Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
    Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.
    Zheng C; Lu F; Chen B; Yang J; Yu H; Wang D; Xie H; Chen K; Xie Y; Li J; Bo Z; Wang Y; Chen G; Deng T
    Cancer Sci; 2023 Dec; 114(12):4717-4731. PubMed ID: 37778742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
    Tang Y; Zhou H; Xiang Y; Cui F
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
    Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
    Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Analysis of Microbiome and Transcriptome Data Reveals the Interplay Between Commensal Bacteria and Fibrin Degradation in Endometrial Cancer.
    Li C; Gu Y; He Q; Huang J; Song Y; Wan X; Li Y
    Front Cell Infect Microbiol; 2021; 11():748558. PubMed ID: 34621695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
    J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.
    Jinato T; Anuntakarun S; Satthawiwat N; Chuaypen N; Tangkijvanich P
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):34. PubMed ID: 38183473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma.
    Jin Y; Lee WY; Toh ST; Tennakoon C; Toh HC; Chow PK; Chung AY; Chong SS; Ooi LL; Sung WK; Lee CG
    J Transl Med; 2019 Aug; 17(1):273. PubMed ID: 31429776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
    Yang J; He Q; Lu F; Chen K; Ni Z; Wang H; Zhou C; Zhang Y; Chen B; Bo Z; Li J; Yu H; Wang Y; Chen G
    Gut Microbes; 2023; 15(1):2201159. PubMed ID: 37089022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctly altered gut microbiota in the progression of liver disease.
    Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
    Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
    Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.
    Deng T; Li J; He B; Chen B; Liu F; Chen Z; Zheng J; Shi Z; Zhang T; Deng L; Yu H; Yang J; Wu L; Shan Y; Yu Z; Chen X; Wang Y; Chen G
    Hepatol Int; 2022 Feb; 16(1):99-111. PubMed ID: 35064546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Chen T; Ding R; Chen X; Lu Y; Shi J; Lü Y; Tang B; Zhang W; Ye C; Yuan M; Yang Z
    Bioengineered; 2021 Dec; 12(1):8233-8246. PubMed ID: 34592890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma.
    Huang JH; Wang J; Chai XQ; Li ZC; Jiang YH; Li J; Liu X; Fan J; Cai JB; Liu F
    Microbiol Spectr; 2022 Oct; 10(5):e0098322. PubMed ID: 36173308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer.
    Yang Y; Misra BB; Liang L; Bi D; Weng W; Wu W; Cai S; Qin H; Goel A; Li X; Ma Y
    Theranostics; 2019; 9(14):4101-4114. PubMed ID: 31281534
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
    Tang Y; Zhang Y; Hu X
    Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
    Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.